111 related articles for article (PubMed ID: 15084979)
21. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
22. Anti-angiogenesis therapy in pancreatic carcinoma.
Saif MW
JOP; 2006 Mar; 7(2):163-73. PubMed ID: 16525200
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
24. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis.
Ishikawa T; Chen J; Wang J; Okada F; Sugiyama T; Kobayashi T; Shindo M; Higashino F; Katoh H; Asaka M; Kondo T; Hosokawa M; Kobayashi M
Oncogene; 2003 Feb; 22(8):1238-42. PubMed ID: 12606950
[TBL] [Abstract][Full Text] [Related]
25. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
[TBL] [Abstract][Full Text] [Related]
26. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
Li L; Braiteh FS; Kurzrock R
Cancer; 2005 Sep; 104(6):1322-31. PubMed ID: 16092118
[TBL] [Abstract][Full Text] [Related]
27. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
[TBL] [Abstract][Full Text] [Related]
28. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
[TBL] [Abstract][Full Text] [Related]
29. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
32. Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF.
Ma JX; Sun YL; Wang YQ; Wu HY; Jin J; Yu XF
Oncol Res; 2013; 20(8):359-68. PubMed ID: 23924856
[TBL] [Abstract][Full Text] [Related]
33. Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-β/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs.
Lin SZ; Xu JB; Ji X; Chen H; Xu HT; Hu P; Chen L; Guo JQ; Chen MY; Lu D; Wang ZH; Tong HF
Mol Med Rep; 2015 Oct; 12(4):5865-71. PubMed ID: 26238071
[TBL] [Abstract][Full Text] [Related]
34. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
35. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Eibl G; Takata Y; Boros LG; Liu J; Okada Y; Reber HA; Hines OJ
Cancer Res; 2005 Feb; 65(3):982-90. PubMed ID: 15705899
[TBL] [Abstract][Full Text] [Related]
36. [Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude mice].
Zhou XC; Tang CW; Liu CL; Wang CH
Ai Zheng; 2004 Apr; 23(4):376-80. PubMed ID: 15087022
[TBL] [Abstract][Full Text] [Related]
37. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo.
Kawarada Y; Ishikura H; Kishimoto T; Saito K; Takahashi T; Kato H; Yoshiki T
Pancreas; 1997 Oct; 15(3):251-7. PubMed ID: 9336788
[TBL] [Abstract][Full Text] [Related]
39. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
Martínez-Bosch N; Guerrero PE; Moreno M; José A; Iglesias M; Munné-Collado J; Anta H; Gibert J; Orozco CA; Vinaixa J; Fillat C; Viñals F; Navarro P
Oncotarget; 2016 Jul; 7(30):48265-48279. PubMed ID: 27374084
[TBL] [Abstract][Full Text] [Related]
40. Periostin Limits Tumor Response to VEGFA Inhibition.
Keklikoglou I; Kadioglu E; Bissinger S; Langlois B; Bellotti A; Orend G; Ries CH; De Palma M
Cell Rep; 2018 Mar; 22(10):2530-2540. PubMed ID: 29514082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
